E. Galanis

944 total citations
17 papers, 656 citations indexed

About

E. Galanis is a scholar working on Molecular Biology, Genetics and Genetics. According to data from OpenAlex, E. Galanis has authored 17 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Genetics and 5 papers in Genetics. Recurrent topics in E. Galanis's work include Glioma Diagnosis and Treatment (7 papers), Virus-based gene therapy research (5 papers) and Cancer Research and Treatments (3 papers). E. Galanis is often cited by papers focused on Glioma Diagnosis and Treatment (7 papers), Virus-based gene therapy research (5 papers) and Cancer Research and Treatments (3 papers). E. Galanis collaborates with scholars based in United States and Canada. E. Galanis's co-authors include David H. Kirn, James L. Abbruzzese, Joseph Rubin, M. Jason Hatfield, Daniel Y. Sze, T. Reid, James C. Andrews, Carla Heise, James Andrews and Lawrence M. Wein and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

E. Galanis

17 papers receiving 637 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Galanis United States 9 430 340 289 112 109 17 656
Jennifer Coleman United States 11 447 1.0× 266 0.8× 405 1.4× 45 0.4× 81 0.7× 19 677
R L Martuza United States 12 704 1.6× 436 1.3× 377 1.3× 104 0.9× 54 0.5× 13 916
Singh Gagandeep United States 6 358 0.8× 237 0.7× 149 0.5× 107 1.0× 13 0.1× 7 494
Timo Joensuu Finland 18 716 1.7× 367 1.1× 668 2.3× 176 1.6× 11 0.1× 27 893
John Lam United States 13 808 1.9× 634 1.9× 582 2.0× 159 1.4× 31 0.3× 24 949
Maxine Bauzon United States 12 397 0.9× 303 0.9× 361 1.2× 89 0.8× 13 0.1× 25 606
Arnold Kloos Germany 14 276 0.6× 220 0.6× 408 1.4× 65 0.6× 25 0.2× 27 630
Felix G. Hermann Germany 12 252 0.6× 349 1.0× 151 0.5× 15 0.1× 113 1.0× 16 621
Klaus Mantwill Germany 15 341 0.8× 405 1.2× 301 1.0× 83 0.7× 22 0.2× 25 631
Evidio Domingo‐Musibay United States 12 148 0.3× 115 0.3× 239 0.8× 18 0.2× 42 0.4× 32 504

Countries citing papers authored by E. Galanis

Since Specialization
Citations

This map shows the geographic impact of E. Galanis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Galanis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Galanis more than expected).

Fields of papers citing papers by E. Galanis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Galanis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Galanis. The network helps show where E. Galanis may publish in the future.

Co-authorship network of co-authors of E. Galanis

This figure shows the co-authorship network connecting the top 25 collaborators of E. Galanis. A scholar is included among the top collaborators of E. Galanis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Galanis. E. Galanis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Venur, Vyshak Alva, Sandro Santagata, E. Galanis, & Priscilla K. Brastianos. (2018). New molecular targets in meningiomas: the present and the future. Current Opinion in Neurology. 31(6). 740–746. 14 indexed citations
3.
Brown, Paul D., Karla V. Ballman, Jane H. Cerhan, et al.. (2016). N107C/CEC.3: A Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease. International Journal of Radiation Oncology*Biology*Physics. 96(5). 937–937. 26 indexed citations
4.
Brown, Paul D., S. Keith Anderson, Xiomara W. Carrero, et al.. (2015). Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance). Neuro-Oncology Practice. 2(4). 199–204. 26 indexed citations
5.
Brown, Paul E., Anthony L. Asher, Karla V. Ballman, et al.. (2015). BMET-05NCCTG N0574 (ALLIANCE): A PHASE III RANDOMIZED TRIAL OF WHOLE BRAIN RADIATION THERAPY (WBRT) IN ADDITION TO RADIOSURGERY (SRS) IN PATIENTS WITH 1 TO 3 BRAIN METASTASES. Neuro-Oncology. 17(suppl 5). v45.5–v46. 18 indexed citations
6.
Studebaker, Adam, Brian Hutzen, Christopher R. Pierson, et al.. (2012). Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro-Oncology. 14(4). 459–470. 37 indexed citations
7.
Jaeckle, Kurt A., David Schiff, E. Galanis, et al.. (2011). NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.. Journal of Clinical Oncology. 29(15_suppl). 2033–2033. 3 indexed citations
8.
Carrero, Xiomara W., Teresa K. Kimlinger, Surendra Kumar, et al.. (2011). Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR).. Journal of Clinical Oncology. 29(15_suppl). 2019–2019. 2 indexed citations
9.
Sarkaria, Jann N., E. Galanis, Wenting Wu, et al.. (2010). Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks. Clinical Cancer Research. 16(22). 5573–5580. 56 indexed citations
10.
Galanis, E., Kurt A. Jaeckle, Shannon W. Anderson, et al.. (2010). NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.. Journal of Clinical Oncology. 28(15_suppl). 2018–2018. 5 indexed citations
11.
12.
Galanis, E., Lynn C. Hartmann, William A. Cliby, et al.. (2008). Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa). Journal of Clinical Oncology. 26(15_suppl). 5538–5538. 7 indexed citations
13.
Galanis, E., Kurt A. Jaeckle, Matthew J. Maurer, et al.. (2007). N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology. 25(18_suppl). 2004–2004. 13 indexed citations
14.
Richards, Jon, A. Y. Bedikian, René González, et al.. (2005). High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial. Journal of Clinical Oncology. 23(16_suppl). 7543–7543. 5 indexed citations
15.
Richards, Jon, A. Y. Bedikian, René González, et al.. (2004). A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Journal of Clinical Oncology. 22(14_suppl). 7509–7509. 1 indexed citations
16.
Reid, Tony, E. Galanis, James L. Abbruzzese, et al.. (2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.. PubMed. 62(21). 6070–9. 251 indexed citations
17.
Reid, T., E. Galanis, James L. Abbruzzese, et al.. (2001). Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy. 8(21). 1618–1626. 185 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer Coleman Breakdown of academic impact, for papers by R L Martuza Breakdown of academic impact, for papers by Singh Gagandeep Breakdown of academic impact, for papers by Timo Joensuu Breakdown of academic impact, for papers by John Lam Breakdown of academic impact, for papers by Maxine Bauzon Breakdown of academic impact, for papers by Arnold Kloos Breakdown of academic impact, for papers by Felix G. Hermann Breakdown of academic impact, for papers by Klaus Mantwill Breakdown of academic impact, for papers by Evidio Domingo‐Musibay
Rankless by CCL
2026